ribavirin has been researched along with citalopram in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (42.86) | 29.6817 |
| 2010's | 12 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Farah, A | 1 |
| Biglia, A; Blanch, J; Blanco, JL; de Pablo, J; García, F; Gatell, JM; Laguno, M; Larrousse, M; León, A; Lonca, M; Mallolas, J; Martinez, E; Miró, JM; Murillas, J | 1 |
| Berg, T; Garkisch, AS; Heinz, A; Hinzpeter, A; Pich, M; Schaefer, M; Schwaiger, M; Uebelhack, R; van Boemmel, F | 1 |
| Fucci, JC; Gleason, OC; Philipsen, MA; Yates, WR | 1 |
| Annable, L; Benkelfat, C; Brouillette, MJ; Cooper, C; Klein, MB; Kraus, D; Sheehan, NL; Singer, J; Weston, F | 1 |
| Arribas, JR; Fraile, JM; González, JJ; Montes, ML | 1 |
| Keicher, C; Kraus, MR; Rieger, P; Schäfer, A; Scheurlen, M; Seufert, J; Weissbrich, B | 1 |
| Ackermann, G; Waizmann, M | 1 |
| Ardèvol, M; Castellví, P; Costa, J; Diago, M; Diez-Quevedo, C; Giménez, D; Giner, P; Martín-Santos, R; Masnou, H; Morillas, RM; Navinés, R; Planas, R; Pretel, J; Solà, R | 1 |
| Bezemer, G; de Knegt, RJ; Drenth, JP; Droogleever Fortuyn, HA; Hansen, BE; Hengeveld, MW; Janssen, HL; Van Gool, AR; Weegink, CJ | 1 |
| Hou, XJ; Wang, J; Xu, JH; Yu, YY | 1 |
| Bezemer, G; de Knegt, RJ; Hansen, BE; Hotho, DM; Janssen, HL; Van Gool, AR; Veldt, BJ | 1 |
| Feld, JJ; Shah, H; Sheehan, K; Sockalingam, S | 1 |
2 review(s) available for ribavirin and citalopram
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Can antidepressants prevent pegylated interferon-α/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials?
Topics: Antidepressive Agents; Antiviral Agents; Citalopram; Depression; Double-Blind Method; Hepatitis C, Chronic; Humans; Interferon-alpha; Paroxetine; Polyethylene Glycols; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome | 2013 |
5 trial(s) available for ribavirin and citalopram
| Article | Year |
|---|---|
Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C.
Topics: Adult; Antidepressive Agents, Second-Generation; Antiviral Agents; Citalopram; Depressive Disorder, Major; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Dropouts; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors | 2005 |
CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy.
Topics: Antidepressive Agents, Second-Generation; Antiviral Agents; Canada; Citalopram; Depression; Double-Blind Method; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Psychometrics; Recombinant Proteins; Ribavirin; Sample Size; Severity of Illness Index; Treatment Outcome | 2008 |
Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antiviral Agents; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Psychiatric Status Rating Scales; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Anxiety Disorders; Citalopram; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2011 |
Effects of escitalopram prophylaxis during antiviral treatment for chronic hepatitis C in patients with a history of intravenous drug use and depression.
Topics: Aged; Antiviral Agents; Citalopram; Comorbidity; Depression; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Placebos; Ribavirin; Selective Serotonin Reuptake Inhibitors; Substance Abuse, Intravenous; Treatment Outcome; Young Adult | 2014 |
14 other study(ies) available for ribavirin and citalopram
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Interferon-induced depression treated with citalopram.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Middle Aged; Ribavirin; Treatment Outcome | 2002 |
Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Ribavirin | 2004 |
Preventing relapse of major depression during interferon-alpha therapy for hepatitis C--A pilot study.
Topics: Adolescent; Adult; Antidepressive Agents; Antiviral Agents; Citalopram; Depression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Pilot Projects; Quality of Life; Ribavirin; Secondary Prevention; Severity of Illness Index; Treatment Outcome | 2007 |
[Chorea during treatment with pegylated interferon and ribavirin in HIV-HCV coinfected patient].
Topics: Adult; Anti-HIV Agents; Antidepressive Agents; Antiviral Agents; Anxiety Disorders; Chorea; Citalopram; Depressive Disorder; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Hypothyroidism; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Polypharmacy; Recombinant Proteins; Ribavirin; Sensation Disorders; Thyroiditis, Autoimmune; Thyroxine | 2009 |
Platelet serotonin (5-HT) levels in interferon-treated patients with hepatitis C and its possible association with interferon-induced depression.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Blood Platelets; Citalopram; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Selective Serotonin Reuptake Inhibitors; Serotonin; Time Factors; Young Adult | 2010 |
High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin.
Topics: Adult; Antidepressive Agents; Antiviral Agents; Buprenorphine; Citalopram; Depression; Directly Observed Therapy; Drug Administration Schedule; Female; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Methadone; Middle Aged; Narcotics; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Substance Abuse Treatment Centers; Substance Abuse, Intravenous; Treatment Outcome; Young Adult | 2010 |
Psychiatric care during hepatitis C treatment: the changing role of psychiatrists in the era of direct-acting antivirals.
Topics: Antidepressive Agents; Antiviral Agents; Citalopram; Comorbidity; Cooperative Behavior; Delirium; Depressive Disorder; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Forecasting; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interdisciplinary Communication; Interferon alpha-2; Interferon-alpha; Male; Mianserin; Middle Aged; Mirtazapine; Physician's Role; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2015 |